Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Cash from Financing Activities for 14 consecutive years, with $64.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 1386.32% year-over-year to $64.1 million, compared with a TTM value of $42.5 million through Dec 2025, up 268.25%, and an annual FY2025 reading of -$26.6 million, up 3.65% over the prior year.
  • Cash from Financing Activities was $64.1 million for Q4 2025 at Enanta Pharmaceuticals, up from -$8.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $199.9 million in Q2 2023 and bottomed at -$8.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $11.5 million, with a median of $139000.0 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 4751.33% in 2023, then tumbled 31269.57% in 2024.
  • Year by year, Cash from Financing Activities stood at $9.6 million in 2021, then crashed by 96.88% to $301000.0 in 2022, then plummeted by 2541.86% to -$7.4 million in 2023, then soared by 32.16% to -$5.0 million in 2024, then surged by 1386.32% to $64.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for ENTA at $64.1 million in Q4 2025, -$8.3 million in Q3 2025, and -$6.4 million in Q2 2025.